Fulcrum Therapeutics Announces Proposed $150M Public Offering Of Common Stock

Fulcrum Therapeutics, Inc.® ("Fulcrum") (NASDAQ:FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases, today announced that it has commenced an underwritten public offering of $150.0 million of shares of its common stock. Fulcrum also intends to grant the underwriters a 30-day option to purchase up to an additional $22.5 million of shares of its common stock offered in the proposed public offering. All of the shares in the proposed offering are to be sold by Fulcrum.

J.P. Morgan, Leerink Partners, and Cantor are acting as book-running managers for the proposed offering. Oppenheimer & Co. and Truist Securities are also acting as book-running managers for the proposed offering. The proposed offering is subject to market and other conditions, and there can be no assurance as to whether or when the proposed offering may be completed, or as to the actual size or terms of the proposed offering.